Kesios is developing drug candidates that exploit a novel target within the nuclear factor kappa B (NF-κB) pathway, aimed at restoring apoptosis in myeloma cancer cells. Its lead candidate, KES-0001, is about to enter clinical studies as a potential treatment for multiple myeloma. The company was created to commercialise research led by Professor Guido Franzoso from Imperial College London. Kesios has assembled an experienced management team including CEO Paolo Paoletti, CMO Jane Robertson, CSO Peter Charlton and COO Dayle Hogg. The firm emphasizes a targeted oncology approach and an innovative global clinical path to evaluate impact on patients. Its development and clinical plans are supported by a recent institutional financing round and strategic investor board appointments. Kesios Therapeutics was created to commercialise research led by Professor Guido Franzoso of Imperial College London and is led by CEO Alain Maiore. The company focuses on discovering and developing novel therapeutics targeting multiple myeloma and other hematologic malignancies. Its core product efforts are drug discovery and preclinical development across a pipeline of cancer drug candidates. Kesios plans to use recent funding to advance its pipeline, validate therapeutic opportunities for its candidates, and build out its operational team. The company is based in London, UK and was financed in a seed round reported in 2014. Financially, the seed funding provides early-stage capital to progress programs toward further development milestones.

Total raised

$31M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2015